Navigation Links
For first time, drug developed based on zebrafish studies passes Phase I clinical trial
Date:10/21/2013

Boston, Mass., October 18, 2013 Zebrafish research achieved a significant milestone when the first drug developed through studies utilizing the tiny animal and then put into clinical trials passed a Phase 1 trial aimed at establishing its safety. The drug, discovered in the laboratory of Leonard Zon, MD, at Boston Children's Hospital, has already advanced to Phase II studies designed to determine its efficacy.

Results of the safety trial were reported recently in the journal Blood. At only six years after Zon's laboratory reported the discovery of the chemical from which the drug is derived, the Phase 1 data underscore the potential of zebrafish research to accelerate the journey from bench to bedside.

"The zebrafish is a very good system for evaluating potential drugs," Zon said. "When you discover a new treatment option and can see it go into patients, it's quite a remarkable feeling."

The drug, which is being developed by Fate Therapeutics under the name ProHema, is the result of the Zon laboratory's search for a way to improve the success of hematopoietic stem cell (HSC) transplants using umbilical cord blood. ProHema is a chemical derivative of prostaglandin E2 (PGE2) that, according to preclinical and clinical data, might improve engraftment of transplanted umbilical cord blood cells by helping donated cells home in on the bone marrow.

Although umbilical cords are an effective transplant source in patients for whom a suitable donor cannot be found, a single umbilical cord rarely contains enough HSCs for a transplant for an adult patient. The current method is to use two cord blood units per transplant, raising the risk that the immune cells that arise from the two cords may start to attack each other. In addition, umbilical cords are expensive and in limited supply.

This problem has led Zon, a co-author of the Blood study, and other researchers to search for molecules that could help expand co
'/>"/>

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-7379
Boston Children's Hospital
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. First contact: Early intervention key in diagnosis and treatment of serious mental illness
3. Donor Kidney Re-Used in Second Patient After Failing in First
4. Many Who First Misuse Prescription Pills Get Them From Friends, Family: Report
5. First-of-its-kind Menopause Map helps women navigate treatment
6. First recipients of AcademyHealths Presidential Scholarship announced
7. Kessler Foundation researchers present at first International Congress on Cognition in MS
8. Whos the Dad? First-Trimester Blood Test May Tell
9. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
10. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
11. First study investigating possible link between sunscreen ingredient and endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
For first time, drug developed based on zebrafish studies passes Phase I clinical trial
(Date:5/26/2015)... 26, 2015 Over 700 doctors, nutritionists, ... to the secretaries of the U.S. Department of ... Services urging them to embrace the 2015 Dietary Guidelines ... plants for human health, economic prosperity, and our nation’s ... signed the letter, including: Dr. David Katz, founding director ...
(Date:5/26/2015)... 26, 2015 The American Association of ... 55 poison centers applaud the efforts of the United ... according to Stephen T. Kaminski, JD, AAPCC CEO and ... Substances Act, introduced by Senator Edward J. Markey on ... opioid pain medications and other controlled substances to undergo ...
(Date:5/26/2015)... Grove Village, IL (PRWEB) May 26, 2015 ... getting ready for the summer season, and thanks ... in hearing wellness solutions, more of their musicians ... earplugs. , With over 400 participating groups, ... Vic Firth Earplugs by Etymotic are now for ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Octo Consulting ... and management consulting solutions to the federal marketplace, has ... and Cloud Solutions. In this newly created role, Pal ... and growth in cloud computing, big data, and digital ... expanding leadership team as we continue to bring clients ...
(Date:5/26/2015)... Relias Learning , the leader ... and human services market, announces expansion of their user ... attendance and participation in 2014, they will double the ... user conference an exciting new facelift. , Regional ... and discuss best practices, share their expertise, provide feedback ...
Breaking Medicine News(10 mins):Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 2Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 3Health News:American Association of Poison Control Centers Supports Legislative Initiatives Targeting the Responsible Prescription of Opioid Pain Medication 2Health News:American Association of Poison Control Centers Supports Legislative Initiatives Targeting the Responsible Prescription of Opioid Pain Medication 3Health News:Marching Musicians Getting In Step With Hearing Protection 2Health News:Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions 2Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3
... News) -- The first artificial heart valve that can ... the U.S. Food and Drug Administration. The Sapien ... heart valve damaged by senile aortic valve stenosis, a ... cause the valve to narrow. One expert called ...
... inserted in the cerebral cortex of a rat model turns nearly ... less of the tough scarring that walls off hard probes that ... In the first test of the nanocomposite probe inspired by ... compared to that of a metal probe, and appeared to enable ...
... time, researchers have combined gene therapy and stem ... bleeding disorder hemophilia A in large animals, opening ... for human patients. Researchers at Wake Forest ... with other institutions, report in Experimental Hematology ...
... firefighters for the range of scenarios they are ... Michael R. Baumann, Carol L. Gohm, and Bryan ... Factors article, "Phased Training for High-Reliability Occupations: ... the value of current scenario-based training programs. ...
... Nov. 2 (HealthDay News) -- A rare occurrence of people ... same time has been confirmed by researchers. The co-infection ... strain called H3N2 was identified in a young Cambodian boy ... the genomes of both viruses showed that the viruses did ...
... Epstein-Barr virus (EBV) infects nine out of ten people ... early childhood often cause no disease symptoms, but people ... mononucleosis, a disease characterized by swollen lymph nodes, fever ... kinds of cancer, including Hodgkin lymphoma and stomach and ...
Cached Medicine News:Health News:FDA OKs Heart Valve That Does Not Require Open-Heart Surgery 2Health News:FDA OKs Heart Valve That Does Not Require Open-Heart Surgery 3Health News:Brain probe that softens after insertion causes less scarring 2Health News:Brain probe that softens after insertion causes less scarring 3Health News:Gene therapy shows promise as hemophilia treatment in animal studies 2Health News:Current training programs may not prepare firefighters to combat stress 2Health News:It's Possible to Come Down With Two Flu Viruses at Once 2Health News:NIH scientists outline steps toward Epstein-Barr virus vaccine 2
(Date:5/26/2015)... SAN DIEGO , May 26, 2015 /PRNewswire/ ... in developing targeted therapeutic devices to address infectious ... A. Joyce , Chief Executive Officer, will present ... on Thursday, May 28th.  Details of Aethlon Medical,s ... Microcap Investor Conference Date: , Thursday, May 28, ...
(Date:5/26/2015)... , May 26, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York City. The public is welcome to ... the Array BioPharma website.Event: Jefferies 2015 Global Healthcare ... p.m. Eastern Time Webcast: www.arraybiopharma.com  About Array BioPharma ...
(Date:5/26/2015)... 26, 2015  LabStyle Innovations Corp. (DRIO), ... announced today that in partnership with ... Healthcare, it has launched  the comprehensive Dario™ ... advanced Telecare unit (MOMA). The Dario™ is ... enables remote treatment for diabetes aiming to ...
Breaking Medicine Technology:Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 2Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 3Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 4LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4
... Carrot Medical, a leading manufacturer of integrated medical imaging display ... the year, Carrot Medical achieved significant growth in sales and ... half of 2011 with record second quarter sales, Carrot surpassed ...  The company is now well positioned for the third straight ...
... comedienne and TV favourite Jo Brand has joined forces with ... brand new comedy film (54 seconds) to launch Macmillan Cancer ... Jo Brand running around South London, in what looks like ... with Joanna Scanlan and produces a pint of milk; it ...
Cached Medicine Technology:Carrot Medical Positioned for Third Straight Year of Triple Digit Growth 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 3
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Medicine Products: